AzTrials
AzTrials

IBS - Irritable Bowel SyndromePhase 1/2IBSNCT04422327

The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome

A Phase 1/2 study testing Probiotic capsule in people with IBS - Irritable Bowel Syndrome and Depression, Anxiety, run by PrecisionBiotics Group Ltd. at 1 site in Ireland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aimed to assess the impact of consumption of COMBO, a combination product of two Bifidobacterium longum strains, on stress, mood and bowel symptoms in adults with Irritable Bowel Syndrome (IBS). Read more about this study

Who is it for?
Ages 18 to 55 years, women only
What is being tested?
Probiotic capsule
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteIreland
Study dates
20 Sep 2017to 12 Feb 2018
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • To be considered eligible for enrolment into the study, subjects must;
  • Be able to give written informed consent,
  • Be a Caucasian female, between 18 and 55 years of age,
  • Subject has Irritable Bowel Syndrome according to the Rome III Diagnostic Criteria:
  • Recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months associated with two or more of the following:
  • Improvement with defecation
Show all 17Show fewer
  • Onset associated with a change in frequency of stool
  • Onset associated with a change in form (appearance) of stool
  • Criterion fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis
  • "Discomfort" means an uncomfortable sensation not described as pain.
  • Subjects agree to complete symptom diaries and return completed diaries at all sessions,
  • Subjects with mild to moderate score (8-14) on the HADS-A and/or HADS-D questionnaire, Subjects will be excluded if there is greater than 1 point difference from the screening to baseline scores,
  • Be willing to refrain from taking any dietary supplements or other fermented foods that contain live bacteria during the study,
  • Be willing to refrain from taking any medications or preparations used in the therapy of IBS (herbal, dietary supplements, homeopathic preparations, etc.) during the study and from 4-weeks before the baseline visit,
  • Be willing to refrain from probiotic use 4 weeks before the baseline visit,
  • If using fiber supplements (e.g., Trifyba, Fybogel, Konsyl, Isogel, Regulan, Ispagel, Celevac, Normacol), the dose and regimen have remained stable for at least 30 days and the subject will continue the same dose and regimen throughout the length of the trial,
  • If using products that contain nicotine or caffeine, agrees to continue current usage levels throughout the length of the trial.

Who cannot join

  • Subjects will be excluded from the study if they meet any of the below criteria;
  • Are less than 18 and greater than 55 years of age at the time of consent,
  • Females are pregnant, lactating or wish to become pregnant during the study. Female subject is currently either of:
  • non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or any female who is surgically sterilized (via documented hysterectomy or bilateral tubal ligation). (For purposes of this study, postmenopausal is defined as one year without menses), OR
  • child bearing potential, the subject is eligible to enter and participate in this study if she is not lactating and has a negative urine pregnancy test at the screening visit, visit 2 and upon completion of the study at visit 7. The subject must also agree to one of the following methods of contraception:
  • Complete abstinence from intercourse two weeks prior to administration of study drug, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the study medication in cases where subject discontinues the study prematurely. (Subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit.) or,
Show all 30Show fewer
  • has a male sexual partner who is surgically sterilized prior to the Screen Visit and is the only male sexual partner for that subject or,
  • sexual partner(s) is/are exclusively female or,
  • Oral contraceptives (either combined or progestogen only) with double-barrier method of contraception consisting of spermicide with either condom or diaphragm. (Women of child-bearing potential using an oral contraceptive in combination with a double-barrier method of contraception are required to continue to use this form of contraception for 1 week following discontinuation of study medication).
  • Use of double-barrier contraception, specifically, a spermicide plus a mechanical barrier (e.g. male condom, female diaphragm). The subject must be using this method for at least 1 week following the end of the study or,
  • Use of any intrauterine device (IUD) or contraceptive implant with published data showing that the highest expected failure rate is less than 1% per year. The subject must have the device inserted at least 2 weeks prior to the first Screen Visit, throughout the study, and 2 weeks following the end of the study,
  • Are hypersensitive to any of the components of the test product,
  • Consumption of Alflorex probiotic for 6 months,
  • Consumption of any type of yoghurts or probiotic-containing products in the 4 weeks prior to the baseline visit,
  • Subjects who have been on antibiotics during the past month,
  • Concurrent systemic disease and/or laboratory abnormalities considered by Investigators to be risky or that could interfere with data collection,
  • Subjects who have a significant acute or chronic coexisting illness [cardiovascular, history of co-existing gastrointestinal, and/or gynecological, and/or urologic pathology (eg., colon cancer, colitis, Crohn's, celiac, endometriosis, prostate cancer) or lactose intolerance,
  • Subjects with inflammatory disorders (e.g. chronic fatigue syndrome (CDC criteria), psoriasis, rheumatoid arthritis or any other inflammatory arthropathies),
  • Subjects who are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy within the last year),
  • Psychiatric diagnosis other than anxiety or depression,
  • Subjects who are on anti-depressants, anxiolytics, antipsychotics, anticonvulsants, centrally acting corticosteroids and/or opioid pain relievers in the last 6 months,
  • Subject has IBS symptoms that are predominantly related to menstruation,
  • Subject has a history of prior gastrointestinal surgery (apart from appendectomy),
  • Subjects who have had a previous cholecystectomy,
  • Subjects with a history of active cancer in the last 5 years (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected),
  • Subjects with a history of drug and / or alcohol abuse at the time of enrolment,
  • Subject has a history of non-compliance,
  • Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial,
  • If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study,
  • Have a malignant disease or any concomitant end-stage organ disease.

Trial locations and contacts

1 site in 1 country.

Ireland1 site

  • Atlantia Food Clinical Trials Ltd.

    Cork

Other trials in Ireland

About this study

Official title: An Open Label Study to Assess the Impact of 'COMBO' on Mood, Stress and Bowel Symptoms in Adults With Irritable Bowel Syndrome (IBS)

This study aimed to assess the impact of consumption of COMBO, a combination product of two Bifidobacterium longum strains, on stress, mood and bowel symptoms in adults with Irritable Bowel Syndrome (IBS).

Read the detailed description

This is an open label study designed to assess the impact on stress, mood and bowel symptoms \& safety of COMBO, a combination of Bifidobacterium longum 35624® and Bifidobacterium longum 1714™ strains, when consumed once daily for 8 weeks, in adults with Irritable Bowel Syndrome (IBS). Volunteers will be screened according to the selection criteria in order to identify up to 40 female subjects, with recurrent abdominal pain/discomfort and mild to moderate stress/mood status. The study will involve 6 visits over an 18 to 20-week period [Screening period (Visit 1: week-2), Intervention period (Visit 2: week 0, Visit 3: week 4, Visit 4: week 8), and Follow-up/ Washout period (Visit 5: week 12, Visit 6: week 16)]. Participants will fill in daily and weekly eDiary from 1st visit onwards. Questionnaires will be administered from visit 2 to visit 6. Research blood and saliva will also be collected at these time points. Stool sample will be collected at Visit 2, 4, 5, 6.

Being tested
Probiotic capsule
Keywords
Combination of probiotics, Bifidobacterium longum 35624®, Bifidobacterium longum 1714™, depression, anxiety, bowel symptoms, Irritable Bowel Syndrome (IBS), Sleep quality, Cognition, Safety
Medical subject headings
Irritable Bowel Syndrome, Depression, Anxiety Disorders, Sleep Initiation and Maintenance Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Probiotic capsuleDietary supplement

    Each probiotic capsule contains 5 x 10^8 CFU B. longum 35624® and 5 x 10^8 CFU B. longum 1714™ with corn starch and magnesium stearate.

    The probiotic capsule will be supplied by PrecisionBiotics Ltd.

Study groups in NCT04422327
Study groupRoleWhat they receive
Probiotic capsuleExperimentalThe participants consume one probiotic capsule a day for 8 weeks
Receives: Dietary Supplement: Probiotic capsule

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in stress and mood, assessed by Hospital Anxiety and Depression Scale (HADS) scores

    HADS gives HADS-A and HADS-D scores; minimum score for each is 0, maximum score is 21. Higher scores indicate worse stress/mood.

    Measured: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.

Secondary outcomes (17)

  1. Change in Subject Global Assessment (SGA) of IBS symptoms, assessed by weekly eDiary

    Participants answer the question: "Did you have adequate relief of your IBS symptoms over the past week?" Yes or No.

    Measured: Assessed weekly from baseline to 8 weeks post supplement intake.

  2. Change in Subject Global Assessment (SGA) of abdominal pain/discomfort, assessed by weekly eDiary

    Participants answer the question: "Did you have adequate relief of your abdominal pain and discomfort over the past week?" Yes or No.

    Measured: Assessed weekly from baseline to 8 weeks post supplement intake.

  3. Change in IBS-Symptom Severity Score (IBS-SSS)

    IBS-SSS is a composite score of abdominal pain, number of days with abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life (QoL). Scores range from 0 to 500, with higher scores indicating worse symptoms.

    Measured: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.

  4. Change in stool frequency, assessed by daily eDiary

    Daily diary of number of bowel movements.

    Measured: Assessed daily from baseline to 8 weeks post supplement intake.

  5. Change in stool consistency (Bristol Stool Scale), assessed by daily eDiary

    Daily diary of stool consistency of each bowel movement based on Bristol Stool Scale (Type 1-7).

    Measured: Assessed daily from baseline to 8 weeks post supplement intake.

  6. Change in abdominal pain/discomfort, assessed by daily eDiary

    Daily diary of Visual Analog Scale (VAS) of abdominal pain/discomfort.

    Measured: Assessed daily from baseline to 8 weeks post supplement intake.

  7. Change in abdominal bloating/distension, assessed by daily eDiary

    Daily diary of Visual Analog Scale (VAS) of abdominal bloating/distension.

    Measured: Assessed daily from baseline to 8 weeks post supplement intake.

  8. Change in bowel movement urgency, assessed by daily eDiary

    Daily diary of Visual Analog Scale (VAS) of bowel movement urgency.

    Measured: Assessed daily from baseline to 8 weeks post supplement intake.

  9. Change in straining, assessed by daily eDiary

    Daily diary of Visual Analog Scale (VAS) of straining.

    Measured: Assessed daily from baseline to 8 weeks post supplement intake.

  10. Change in passage of gas, assessed by daily eDiary

    Daily diary of Visual Analog Scale (VAS) of passage of gas.

    Measured: Assessed daily from baseline to 8 weeks post supplement intake.

  11. Change in Visceral Sensitivity Index

    Visceral Sensitivity Index (VSI) is a self-report measure of the gastrointestinal symptom-specific anxiety (GSA) of patients with IBS, in terms of cognitive, emotional and behavioral responses. Sum scores range from 0 to 75 with higher scores indicating more severe GI-specific anxiety.

    Measured: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.

  12. Change in sleep quality, assessed by Pittsburgh Sleep Quality Index (PSQI)

    PSQI global score: minimum score is 0, maximum score is 21. Higher scores indicate worse sleep quality.

    Measured: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.

  13. Change in cognition, assessed by Visual Analogue Scales

    This assessment measures individual question answers related to hedonic tone, anxiety and alertness.

    Measured: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.

  14. Change in cognition, assessed by spatial span test

    This test measures span length, errors, number of attempts and latency.

    Measured: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.

  15. Change in cognition, assessed by Stockings of Cambridge test

    This test measures problems solved in minimum moves, mean moves per n-move problem, initial thinking time per n-move problems and subsequent thinking time per n-move problems.

    Measured: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.

  16. Change in cognition, assessed by Paired Associates Learning test

    This test measures errors, trials, memory scores and stages completed.

    Measured: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.

  17. Safety of the investigational product, assessed by number of participants with treatment-related adverse events

    Safety will be evaluated throughout the study on the basis of incidence of treatment-related serious and non-serious adverse events.

    Measured: Assessed through study completion, an average of 6 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2020
  2. Study start20 Sep 2017
  3. Primary completion12 Feb 2018
  4. Study completion12 Feb 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Open label study, with intervention period followed by follow-up (wash out) period.
Masking
None (open label)
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04422327
Sponsor's protocol ID
AFCRO-079
Acronym
IBS
Status last verified
Jun 2020
First submitted
25 May 2020
Last updated
9 Jun 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Probiotic capsule in people with IBS - Irritable Bowel Syndrome and Depression, Anxiety, run by PrecisionBiotics Group Ltd. at 1 site in Ireland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in stress and mood, assessed by Hospital Anxiety and Depression Scale (HADS) scores (time frame: Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04422327.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in